About Arcutis
Strategic
Collaborators
AstraZeneca
Arcutis and AstraZeneca have entered into a licensing agreement for exclusive worldwide rights to all topical dermatological uses of roflumilast, including the exclusive right to commercialize any resulting products.
Huadong
In August 2023, Arcutis and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong) entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast, a next generation phosphodiesterase type 4 (PDE4) inhibitor, in Greater China and parts of Southeast Asia. Huadong received an exclusive license for both the cream and foam formulations of topical roflumilast for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, and potentially additional dermatological conditions in the future. Arcutis will continue to be responsible for the development and commercialization of ZORYVE® (roflumilast) cream and ZORYVE® (roflumilast) foam in the United States and other geographies.
Sato
In February 2024, Arcutis and Sato Pharmaceutical Co., Ltd. entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast, a next generation phosphodiesterase type 4 (PDE4) inhibitor, in Japan. Sato received an exclusive license for both the cream and foam formulations of topical roflumilast for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, atopic dermatitis, and potentially additional dermatological conditions in the future. Arcutis will continue to be responsible for the development and commercialization of ZORYVE® (roflumilast) cream and ZORYVE® (roflumilast) foam in the United States and other geographies.
Meaningful innovation at a glance.
Download our corporate fact sheet.
Download